Advaxis Inc. buy stratec
Start price
24.01.18
/
50%
€41.67
Target price
03.12.18
€121.77
Performance (%)
-86.69%
End price
03.12.18
€5.55
Summary
This prediction ended on 03.12.18 with a price of €5.55. Massive losses of -86.69% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Advaxis Inc. | - | - | - | - |
| iShares Core DAX® | 1.080% | -2.933% | 12.885% | 14.247% |
| iShares Nasdaq 100 | 0.362% | 7.015% | 36.826% | 57.151% |
| iShares Nikkei 225® | -1.155% | -1.155% | 5.073% | 3.799% |
| iShares S&P 500 | 0.806% | 4.388% | 30.269% | 49.772% |
Comments by stratec for this prediction
In the thread Advaxis Inc. diskutieren
stratec stimmt der Buy-Einschätzung von tamam zu
stratec stimmt am 24.01.2018 der Buy-Einschätzung von tamam mit dem Kursziel 10$ zu.
Überschrift: ADXS has very interesting make-or-break potential, caveat emptor!
Tolerability of ADXS11-001 Lm-LLO Listeria Based Immunotherapy With Mitomycin, Fluorouracil and Radiation for Anal Cancer
ADXS reports that 8 of 9 patients were progression-free at the 42 months mark. If researchers could reproduce this in a wider patient population, then addition of the Lm-based immunotherapy might represent a new standard of care.
(Vom Mitglied beendet)